Patents by Inventor Ling-Mei Wang

Ling-Mei Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180142214
    Abstract: An in vitro method for screening a testing compound to evaluate its potential as a liver drug of the disclosure is provided. The method includes applying the testing compound to cells of an isolated human liver tumor cell line, named as ITRI-H28, measuring a cell viability of the cells and determining the effect of the testing compound on the cells by calculating a half maximal inhibitory concentration (IC50) of the testing compound.
    Type: Application
    Filed: January 3, 2018
    Publication date: May 24, 2018
    Applicant: Industrial Technology Research Institute
    Inventors: Mei-Wei Lin, Dian-Kun Li, Ling-Mei Wang, Ching-Huai Ko, Chin-Pen Lai, Chun-Min Liu, Hsiang-Wen Tseng
  • Publication number: 20180143181
    Abstract: An in vitro method for screening a testing compound to evaluate its potential as a liver drug is provided. The method includes applying the testing compound to cells of an isolated human liver tumor cell line, named as ITRI-H16, measuring a cell viability of the cells and determining the effect of the testing compound on the cells by calculating a half maximal inhibitory concentration (IC50) of the testing compound.
    Type: Application
    Filed: January 3, 2018
    Publication date: May 24, 2018
    Applicant: Industrial Technology Research Institute
    Inventors: Mei-Wei Lin, Dian-Kun Li, Ling-Mei Wang, Ching-Huai Ko, Chin-Pen Lai, Chun-Chung Wang, Hsiang-Wen Tseng
  • Publication number: 20150160195
    Abstract: An isolated human liver tumor cell line is provided and is named as ITRI-H16, and which was deposited in the Food Industry Research and Development Institute with the accession number BCRC960432 on Nov. 7, 2011. A method of an agent screening is also provided. The method includes providing the isolated human liver tumor cell line ITRI-H16 and treating an interest compound to the ITRI-H16 cell line to determine an effect of the interesting compound on the ITRI-H16 cell line.
    Type: Application
    Filed: October 13, 2014
    Publication date: June 11, 2015
    Inventors: Mei-Wei Lin, Dian-Kun Li, Ling-Mei Wang, Ching-Huai Ko, Chin-Pen Lai, Chun-Chung Wang, Hsiang-Wen Tseng
  • Publication number: 20150159141
    Abstract: An isolated human liver tumor cell line is provided, which was named as ITRI-H28 and deposited in the Food Industry Research and Development Institute with the accession number BCRC960457 on Dec. 14, 2012. A method of an agent screening is also provided. The method includes providing the isolated human liver tumor cell line ITRI-H28 and adding an interest compound into the ITRI-H28 cell line to determine an effect on the ITRI-H28 cell line.
    Type: Application
    Filed: October 9, 2014
    Publication date: June 11, 2015
    Inventors: Mei-Wei Lin, Dian-Kun Li, Ling-Mei Wang, Ching-Huai Ko, Chin-Pen Lai, Chun-Min Liu, Hsiang-Wen Tseng
  • Patent number: 8758756
    Abstract: An anti-human epidermal growth factor receptor (EGFR) antibody including an amino acid sequence as set forth in SEQ ID No. 3 is provided. The antibody binding to a labeling agent and used for labeling cells is also provided. A novel method for screening an anti-EGFR antibody is further provided.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: June 24, 2014
    Assignee: Industrial Technology Research Institute
    Inventors: Hsiang-Ching Wang, Ming-Hua Yang, Ling-Mei Wang, Min-Yuan Chou, Jyuan-Jyuan Syu
  • Publication number: 20130171174
    Abstract: An anti-human epidermal growth factor receptor (EGFR) antibody including an amino acid sequence as set forth in SEQ ID No. 3 is provided. The antibody binding to a labeling agent and used for labeling cells is also provided. A novel method for screening an anti-EGFR antibody is further provided.
    Type: Application
    Filed: September 12, 2012
    Publication date: July 4, 2013
    Inventors: Hsiang-Ching WANG, Ming-Hua Yang, Ling-Mei Wang, Min-Yuan Chou, Jyuan-Jyuan Syu
  • Patent number: 7714146
    Abstract: The invention is related to novel azulene-oxindole compounds having formula (I) shown below, wherein one of R1, R2 and R3 represents a moiety of formula (II), each of A1 and A2 independently is nitrogen, oxygen or sulfur, each of the others of R1, R2, R3, R1, R5, R6, R7, R8, R9, R10, R11, R12, R13, and R14 is as recited in the specification. The novel compound potentially inhibits multiple kinases and thus can be used to treat some disease like cancer or inflammatory.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: May 11, 2010
    Assignee: Industrial Technology Research Institute
    Inventors: On Lee, Chrong-Shiong Hwang, Chih-Hung Chen, Yuan-Jang Tsai, Chih-Peng Liu, Ching-Huai Ko, Hsin-Hsin Shen, Ling-Mei Wang, Kuei-Tai Lai, Ying-Chu Shih, Ting-Shou Chen, Yen-Chun Chen, Lain-Tze Lee
  • Publication number: 20080125590
    Abstract: An azulene compound is provided. The azulene compound has formula (I) shown below. Each variable in formula (I) is defined in the specification. One of R1, R2, R3, R4, R5, R6, R7, and R8 in formula (I) is a moiety of formula (II). The compound can be used to treat cancer.
    Type: Application
    Filed: October 31, 2007
    Publication date: May 29, 2008
    Applicant: Industrial Technology Research Institute
    Inventors: On Lee, Chrong-Shiong Hwang, Chih-Hung Chen, Yuan-Jang Tsai, Chih Peng Liu, Ching-Huai Ko, Hsin-Hsin Shen, Ling-Mei Wang, Kuei-Tai Lai, Ying-Chu Shih, Ting-Shou Chen, Yen-Chun Chen, Lain-Tze Lee